CN106061498B - 帕立骨化醇在炎性贫血的治疗中的用途 - Google Patents

帕立骨化醇在炎性贫血的治疗中的用途 Download PDF

Info

Publication number
CN106061498B
CN106061498B CN201580007824.4A CN201580007824A CN106061498B CN 106061498 B CN106061498 B CN 106061498B CN 201580007824 A CN201580007824 A CN 201580007824A CN 106061498 B CN106061498 B CN 106061498B
Authority
CN
China
Prior art keywords
paricalcitol
esa
levels
patients
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580007824.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106061498A (zh
Inventor
米格尔·乔瓦尼·乌里奥尔里韦拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN106061498A publication Critical patent/CN106061498A/zh
Application granted granted Critical
Publication of CN106061498B publication Critical patent/CN106061498B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201580007824.4A 2014-02-11 2015-01-16 帕立骨化醇在炎性贫血的治疗中的用途 Active CN106061498B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201430177 2014-02-11
ES201430177A ES2472040B1 (es) 2014-02-11 2014-02-11 Uso de paricalcitol en el tratamiento de la anemia inflamatoria
PCT/EP2015/050817 WO2015121022A1 (en) 2014-02-11 2015-01-16 Use of paricalcitol in the treatment of inflammatory anaemia

Publications (2)

Publication Number Publication Date
CN106061498A CN106061498A (zh) 2016-10-26
CN106061498B true CN106061498B (zh) 2019-12-06

Family

ID=51205045

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580007824.4A Active CN106061498B (zh) 2014-02-11 2015-01-16 帕立骨化醇在炎性贫血的治疗中的用途

Country Status (16)

Country Link
US (1) US11464791B2 (enExample)
EP (1) EP3104872B1 (enExample)
JP (1) JP2017512753A (enExample)
KR (1) KR20160113664A (enExample)
CN (1) CN106061498B (enExample)
AR (1) AR099330A1 (enExample)
AU (1) AU2015217956B2 (enExample)
CA (1) CA2938057A1 (enExample)
DK (1) DK3104872T3 (enExample)
ES (2) ES2472040B1 (enExample)
IL (1) IL247207B (enExample)
MX (1) MX365096B (enExample)
PT (1) PT3104872T (enExample)
RU (1) RU2016131412A (enExample)
UY (1) UY35989A (enExample)
WO (1) WO2015121022A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102504090B1 (ko) * 2020-08-05 2023-02-24 경상국립대학교병원 조영제-유발 신독성 예방 또는 치료용 약학 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062620A2 (en) * 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
CN102772364A (zh) * 2011-05-13 2012-11-14 重庆华邦制药股份有限公司 帕立骨化醇的脂肪乳及其制剂和制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563874A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants
CN101610782A (zh) * 2007-01-10 2009-12-23 爱迪生药物公司 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062620A2 (en) * 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
CN102772364A (zh) * 2011-05-13 2012-11-14 重庆华邦制药股份有限公司 帕立骨化醇的脂肪乳及其制剂和制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Renal anaemia and EPO hyporesponsiveness associated withvitamin D deficiency: the potential role of inflammation";Andrea Icardi等;《Nephrol Dial Transplant》;20130306;第28卷;第1672–1679页 *

Also Published As

Publication number Publication date
ES2472040R1 (es) 2014-09-18
IL247207B (en) 2020-02-27
US11464791B2 (en) 2022-10-11
AU2015217956B2 (en) 2019-04-04
ES2728158T3 (es) 2019-10-22
US20160367571A1 (en) 2016-12-22
ES2472040B1 (es) 2015-07-01
RU2016131412A (ru) 2018-03-15
CN106061498A (zh) 2016-10-26
MX365096B (es) 2019-05-22
JP2017512753A (ja) 2017-05-25
CA2938057A1 (en) 2015-08-20
DK3104872T3 (da) 2019-06-17
UY35989A (es) 2015-03-27
ES2472040A2 (es) 2014-06-27
KR20160113664A (ko) 2016-09-30
AR099330A1 (es) 2016-07-13
IL247207A0 (en) 2016-09-29
PT3104872T (pt) 2019-06-11
MX2016010104A (es) 2017-01-06
WO2015121022A1 (en) 2015-08-20
EP3104872A1 (en) 2016-12-21
AU2015217956A1 (en) 2016-08-25
EP3104872B1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
Friedrisch et al. Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
Coyne et al. Differential effects of acute administration of 19-Nor-1, 25-dihydroxy-vitamin D2 and 1, 25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients
US8329677B2 (en) Method of treating and preventing secondary hyperparathyroidism
Iguchi et al. Administration of ferric citrate hydrate decreases circulating FGF23 levels independently of serum phosphate levels in hemodialysis patients with iron deficiency
Drueke et al. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies
Hyde et al. In vivo measurement of strontium absorption from the rumen of dairy cows as an index of calcium absorption capacity
Huang et al. Enteral calcium infusion used successfully as treatment for a patient with hereditary vitamin D resistant rickets (HVDRR) without alopecia: a novel mutation
Luo et al. Impact of tacrolimus on bone metabolism after kidney transplantation
Beer et al. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer
Melamed et al. CKD-mineral bone disorder in stage 4 and 5 CKD: what we know today?
JP2012527424A (ja) イネカルシトールの新しい治療的使用
Mori et al. The effect of active vitamin D administration on muscle mass in hemodialysis patients
AU2015217956B2 (en) Use of paricalcitol in the treatment of inflammatory anaemia
Johnson et al. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial
Pandey et al. Use of 2MD, a novel oral calcitriol analog, in hemodialysis patients with secondary hyperparathyroidism
Jacovic et al. Erythropoietin resistance in hemodialysis patients
JP2025031720A (ja) カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物
Tidblad et al. Metabolic effects of growth hormone treatment in short prepubertal children: a double-blinded randomized clinical trial
RU2635541C2 (ru) Способ лечения дряхлости
Petkovich et al. Extended-release calcifediol in renal disease
Bashardoust et al. Treatment effect of ergocalciferol on bone metabolism indexes and parathyroid hormone in hemodialysis patients
Abu-Hamdan et al. Zinc tolerance test in uremia: effect of calcitriol supplementation.
Popat Chronic kidney disease: managing the complications
IT202300007608A1 (it) Composizione liposomiale comprendente ferro solfato per l’uso nella cura e prevenzione dell’anemia in donne in gravidanza e durante il puerperio

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant